Background Antiplatelet agents are widely used to prevent cardiovascular events. The risks
and benefits of antiplatelet agents may be different in people with chronic kidney disease …

Platelet adhesion, activation and aggregation play a pivotal role in atherothrombosis.
Intracoronary atherothrombosis is the most common cause of the development of acute …

Context Despite the widespread use of percutaneous coronary intervention (PCI), the
appropriateness of these procedures in contemporary practice is unknown. Objective To …

Background—Previous studies suggested that statin pretreatment reduces cardiac events in
patients undergoing percutaneous coronary intervention. However, most data were …

An increasing number of patients suffering from cardiovascular disease, especially coronary
artery disease (CAD), are treated with aspirin and/or clopidogrel for the prevention of major …

Background: The choice of antiplatelet therapy after acute coronary syndrome (ACS) is
complicated: Ticagrelor and prasugrel are novel alternatives to clopidogrel, patients with …

Aims The efficacy and safety of ticagrelor vs. clopidogrel in patients with acute coronary
syndromes (ACS) are well documented in the PLATelet inhibition and patient Outcomes trial …

BACKGROUND AND PURPOSE: The optimal antiplatelet regimen after flow diverter
treatment of cerebral aneurysms is still a matter of debate. A single antiplatelet therapy might …

Introduction Dual antiplatelet therapy (DAPT) with aspirin and a thienopyridine (eg,
clopidogrel) prevents stent related thromboembolic events in cardiac patients and is …

Clinicians are faced with the challenge of navigating the precarious balance between
bleeding and clotting. Bleeding disorders or failure to obtain adequate hemostasis during …